evidence/gaps
Cochrane · systematic review · CD011935

Intravesical Bacillus Calmette‐Guérin versus mitomycin C for Ta and T1 bladder cancer

Schmidt, S, Kunath, F, Coles, B, et al. · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library

UrologyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
4
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 1 · 20%Very low 0 · 0%Low 4 · 80%Moderate 0 · 0%High 0 · 0%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

Bacillus Calmette‐Guérin (BCG) compared to mitomycin C (MMC) for Ta and T1 bladder cancer

5 questions
OutcomeEffectEvidenceStatus / GRADE
Time to death from any cause (absolute effect size estimates based on event rate at 5 years).
Bacillus Calmette‐Guérin (BCG) vs mitomycin C (MMC)
HR 0.97 [0.79, 1.2]5 studies · 1132 participantsLow
Downgraded: risk of bias
Serious adverse effects
Bacillus Calmette‐Guérin (BCG) vs mitomycin C (MMC)
RR 2.31 [0.82, 6.52]5 studies · 1024 participantsLow
Downgraded: risk of bias
Time to recurrence (absolute effect size estimates based on event rate at 5 years)
Bacillus Calmette‐Guérin (BCG) vs mitomycin C (MMC)
HR 0.88 [0.71, 1.09]11 studies · 2616 participantsLow
Downgraded: risk of bias
Time to progression (absolute effect size estimates based on event rates at 5 years)
Bacillus Calmette‐Guérin (BCG) vs mitomycin C (MMC)
HR 0.96 [0.73, 1.26]6 studies · 1622 participantsLow
Downgraded: risk of bias
Quality of life (measured using EORTC QLQ‐BLS24 at baseline and after each installation weekly for 6 weeks)
Bacillus Calmette‐Guérin (BCG) vs mitomycin C (MMC)
no estimate extracted1 study · 110 participantsUngraded